Tuning up CAR t: can a better prep boost lymphoma remission?
NCT ID NCT05950802
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to treatment. Researchers want to find the safest and most effective way to prepare the body before giving standard CAR T cell therapy. They are testing different doses of chemotherapy, with or without low-dose radiation, to see if this improves how well the treatment works. The goal is to control the disease and achieve remission, not to provide a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?